Search research articles
Contact Us
Filters
Showing results (11-20 of 54) with videos related to
Page
of 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 3, 2012
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle
L Fornaro, F Crea, G Masi, et al.
Cancer Chemotherapy and Pharmacology
|
October 8, 2008
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
Lorenzo Fornaro, G Masi, S Bursi, et al.
British Journal of Cancer
|
May 25, 2013
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
F Loupakis, M Schirripa, C Caparello, et al.
British Journal of Cancer
|
May 12, 2011
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
M Scartozzi, I Bearzi, A Mandolesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 13, 2006
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
G Masi, L Marcucci, F Loupakis, et al.
The Pharmacogenomics Journal
|
July 3, 2013
Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence
D Páez, A Gerger, W Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2011
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab
M Scartozzi, R Giampieri, E Maccaroni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2010
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients
B Vincenzi, S Galluzzo, D Santini, et al.
The Pharmacogenomics Journal
|
January 9, 2013
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy
F V Negri, A Musolino, N Naldi, et al.
The Pharmacogenomics Journal
|
June 12, 2013
Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy
L Benhaim, A Gerger, P Bohanes, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 54) with videos related to
Sort By:
Page
of 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 3, 2012
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle
L Fornaro, F Crea, G Masi, et al.
Cancer Chemotherapy and Pharmacology
|
October 8, 2008
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
Lorenzo Fornaro, G Masi, S Bursi, et al.
British Journal of Cancer
|
May 25, 2013
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
F Loupakis, M Schirripa, C Caparello, et al.
British Journal of Cancer
|
May 12, 2011
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
M Scartozzi, I Bearzi, A Mandolesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 13, 2006
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
G Masi, L Marcucci, F Loupakis, et al.
The Pharmacogenomics Journal
|
July 3, 2013
Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence
D Páez, A Gerger, W Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2011
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab
M Scartozzi, R Giampieri, E Maccaroni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2010
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients
B Vincenzi, S Galluzzo, D Santini, et al.
The Pharmacogenomics Journal
|
January 9, 2013
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy
F V Negri, A Musolino, N Naldi, et al.
The Pharmacogenomics Journal
|
June 12, 2013
Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy
L Benhaim, A Gerger, P Bohanes, et al.
Page
of 6